De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-Dopa in the MPTP-treated marmoset

Movement Disorders

Volumn 13, Issue 2, 1998, Pages 234-241

  Pearce, Ronald K B ^b   Banerji, Tara ^b   Jenner, Peter ^a   Marsden, C David ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Dyskinesia; Parkinson's disease; Ropinirole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BROMOCRIPTINE; CARBIDOPA; LEVODOPA; ROPINIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CALLITHRIX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; LEVODOPA; MALE; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE D2;

EID: 0031930772     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130207     Document Type: Article

References (42)

1. Nutt JG. Levodopa-induced dyskinesia. Neurology 1990;40:340-345.
2. Rinne UK. New strategies in the treatment of early Parkinson's disease. Acta Neurol Scand 1991;84(suppl 136):95-98.
3. Tolosa, Blesa R, Bayes A, et al. Low-dose bromocriptine in the early phases of Parkinson's disease. Clin Neuropharmacol 1987;19:169-174.
4. Grimes JD, Delgado MR. Bromocriptine problems with low dose in de novo therapy in Parkinson's disease. Clin Neuropharmacol 1985;8:73-77.
5. Devathasan G, Chong PN, Puvanendran K, et al. Low dose bromocriptine therapy in severe Parkinson's disease. Clin Neuropharmacol 1984;7:231-237.
6. Olanow CW, Alberts M. Low dose bromocriptine in previously untreated Parkinson patients. In: Fahn S, Marsden CD, Jenner P, Teychenne P, eds. Recent developments in Parkinson's disease. New York, NY: Raven Press, 1985:315-321.
7. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;43:143-150.
8. Rascol A, Montastruc JL, Guiraud-Chaumeil B, Clanet M. Bromocriptine as the first treatment of Parkinson's disease. Long-term results. Rev Neurol 1982;138:401-408.
9. 3H]spiperone binding. Brain Res 1986;379:294-299.
10. Bédard PJ, Gomez-Mancilla B, Blanchette P, et al. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology, vol 60. New York, NY: Raven Press, 1993:113-118.
11. Teravainen H, Huttunen J, Hietanen M. Initial treatment of parkinsonism with 8-alpha-amino-ergoline. Neurology 1985;35:83-87.
12. Quinn NP, Lang AE, Thompson C, et al. Pergolide in Parkinson's disease. Adv Neurol 1984;40:509-514.
13. Grondin R, Blanchet PJ, Goulet M, et al. Cabergoline as single therapy has a sustained antiparkinsonian action with less dyskinesia in MPTP monkeys. [Abstract]. Mov Disord 1996:11(suppl 1): P216.
14. Agnoli A, Ruggieri S, Baldassarre M, et al. Dopaminergic ergots in parkinsonism. Arch Gen Psychiatry 1980;37:407-417.
15. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
16. Gomez-Mancilla B, Bédard PJ. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413.
17. Pearce RKB, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:231-240.
18. Pearce RKB. Dopamine D1 receptor agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease. Expert Opinion on Therapeutic Patents 1996;6:949-953.
19. Blanchet PJ, Grondin R, Bédard PJ. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 1996;11:91-98.
20. Luquin MR, Laguna J, Obeso JA. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992;31:551-554.
21. Gomez-Mancilla B, Bédard PJ. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188.
22. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
23. Kapoon R, Pirtosek D, Frankel J, et al. Treatment of Parkinson's disease with the novel dopamine D2 agonist ropinirole. Lancet 1989;1:1445-1446.
24. Korczyn AD. A double-blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease. [Abstract]. Neurology 1996;46:S04.003.
25. Kreider M, Knox S. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease. Neurology 1996;46:S67.003.
26. Rascol O. A double-blind L-dopa controlled study of ropinirole in patients with early Parkinson's disease. Neurology 1996;46:S04.005.
27. Wheadon D, Wilson-Lynch K. The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicenter double-blind study. Neurology 1996;46:S04.002.
28. Vidailhet MJ, Bonnet AM, Belal S, et al. Ropinirole without levodopa in Parkinson's disease. Lancet 1990;336:316-317.
29. Bowen WP, Coldwell MC, Hicks GJ, et al. Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D3 receptors. Br J Pharmacol 1993;110:93P.
30. Jenner P, Rupniak NMJ, Rose S, et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984;50:85-90.
31. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
32. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
33. Chen JF, Aloyo VJ, Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases μ opioid receptors in mouse striatum. Neuroscience 1993;54:669-680.
34. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D1 and D2 dopamine agonists. Eur J Pharmacol 1989;168:291-298.
35. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118.
36. Engber TM, Susel Z, Weick BG, et al. Effects of chronic levodopa on D1 and D2 receptor-mediated striatal output. Neurochem Int 1992;20(suppl):255S-260S.
37. 11C]raclopride binding in the rat striatum, quantified using PET. Synapse 1995;21:45-53.
38. Crossman AR. An hypothesis on the pathophysiological mechanisms that underlie levodopaor dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
39. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
40. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994;6:889-897.
41. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
42. DeBoer P, Wachtel SR, Abercrombie ED. Biochemistry and pharmacology of L-dopa in relation to basal ganglia circuitry. In: Percheron G, ed. The basal ganglia IV. New York, NY: Plenum Press, 1994:395-401.